恒瑞医药: 恒瑞医药第九届监事会第十次会议决议公告

Core Points - The company held the 10th meeting of the 9th Supervisory Board on March 28, 2025, via communication, with all 3 supervisors present, confirming compliance with legal and regulatory requirements [1] - The Supervisory Board unanimously approved the 2024 Annual Report and the 2024 Supervisory Board Work Report, affirming that they accurately reflect the company's operational and financial status [1][2] - The company proposed a profit distribution plan for 2024 and discussed anticipated related party transactions for 2025, with all proposals receiving unanimous support from the supervisors [1] - The company reported significant asset losses due to expired products and equipment damage, totaling approximately 850,128 yuan and 58,313,223.37 yuan respectively, and requested to write off these losses [1][2] - The company plans to submit several proposals, including the internal control evaluation report and the remuneration execution report for the Supervisors in 2024, for review at the 2024 Annual General Meeting [2]